Nephrol Dial Transplant. 2023 doi: 10.1093/ndt/gfad167 Epub ahead of print.
These data highlight the consistent benefit of belimumab versus placebo, combined with standard therapy, on kidney outcomes in both newly diagnosed and relapsed patients, and regardless of the use of GC pulses at induction.
Additionally, greater proportions of belimumab treated patients (vs placebo) achieved PERR or CRR at week 104 in both the newly diagnosed and relapsed cohorts.
The observed improvement in patients with relapsed LN is particularly notable given this population is usually more refractory to treatment than patients with newly diagnosed LN.